Results 21 to 30 of about 20,344 (273)
Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice [PDF]
Open Biology, 2019 Osteocytes secrete the glycoprotein sclerostin to inhibit bone formation by osteoblasts, but how sclerostin production is regulated in osteocytes remains unclear.
Wen Liu +14 more
doaj +1 more source
Inhibitors of sclerostin [PDF]
Current Opinion in Rheumatology, 2014 Recent data suggest that inhibitors of sclerostin, an osteocyte-produced Wnt signaling pathway antagonist, can stimulate bone formation. This review provides rationale and summarizes recent evidence supporting this novel approach to skeletal anabolism.Data from numerous preclinical models in rodents and monkeys consistently demonstrate that ...
Matthew T, Drake, Joshua N, Farr
openaire +2 more sources
Journal of Osteoporosis, 2010 The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. One potential new agent is monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis.
openaire +3 more sources
Cardiovascular Safety and Sclerostin Inhibition
The Journal of Clinical Endocrinology & Metabolism, 2021 Abstract Sclerostin, which is primarily produced by the osteocytes, inhibits the canonical Wnt pathway and thereby the osteoblasts and stimulates RANKL release by the osteocytes and thereby osteoclast recruitment. Inhibition of sclerostin therefore causes stimulation of bone formation and inhibition of resorption.
Bente Lomholt Langdahl +2 more
openaire +3 more sources
Cardiovascular Diabetology, 2023 Background Sclerostin is an inhibitor of the Wnt/b-catenin pathway, which regulates bone formation, and can be expressed in vascular smooth muscle cells (VSMCs).
Sheila González-Salvatierra +9 more
doaj +1 more source
Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]
, 2017 Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu +4 more
core +5 more sources
Sclerostin: Another Vascular Calcification Inhibitor? [PDF]
The Journal of Clinical Endocrinology & Metabolism, 2013 Sclerostin, a Wnt antagonist produced by osteocytes, regulates osteoblast activity and is a well-established key player in bone turnover. Recent data indicate that the Wnt pathway may also be involved in vascular calcification.The present study tests the hypothesis that serum sclerostin levels are associated with vascular calcification in patients with
Claes, Kathleen J. +5 more
openaire +3 more sources
Osteocytes and mechanical loading: The Wnt connection [PDF]
, 2019 Bone adapts to the mechanical forces that it experiences. Orthodontic tooth movement harnesses the cell‐ and tissue‐level properties of mechanotransduction to achieve alignment and reorganization of the dentition.
Ahn Y +21 more
core +1 more source
SOST/Sclerostin Improves Posttraumatic Osteoarthritis and Inhibits MMP2/3 Expression After Injury. [PDF]
, 2018 Patients with anterior cruciate ligament (ACL) rupture are two times as likely to develop posttraumatic osteoarthritis (PTOA). Annually, there are ∼900,000 knee injuries in the United States, which account for ∼12% of all osteoarthritis (OA) cases.
Baek +37 more
core +2 more sources
Sclerostin–erbB-3 interactions: Modulation of erbB-3 activity by sclerostin [PDF]
Biochemical and Biophysical Research Communications, 2010 To gain insights into the mechanism of action of sclerostin, a protein that regulates bone mass, we performed yeast two-hybrid analyses using human SOST (sclerostin) cDNA cloned into pGBKT7 DNA-binding domain vector as a bait, and a normalized, high-complexity, universal cDNA library in a GAL4 activating domain vector.
Theodore A, Craig, Rajiv, Kumar
openaire +2 more sources